AN2 Therapeutics, Inc. announced a collaboration agreement with the global biopharma company GSK to develop new therapies for TB (TB). As part of this effort, the Gates Foundation will provide a third year of funding to support AN2's work within the collaboration. TB continues to pose a major global health challenge, affecting more than a quarter of the world's population and causing over 1.25 million deaths annually.
LeuRS is the same validated target underlying epetraborole (in development for NTM lung disease), ganfeborole (in development for TB), and tavaborole, an FDA-approved antifungal.
